IVD Dossier Readiness: Linking Intended Use to Performance Evidence

Start with the decision

Define the analyte, specimen, population, clinical purpose, user and setting precisely. Convert performance claims into traceable metrics and acceptance criteria.

The source basis is MDS-REQ 1 Medical Devices Marketing Authorization and MDS-G028 Bundling Criteria within a Single MDMA Application. Regulatory statements come from those sources; the workflow and review tools are Basier professional recommendations.

Build the evidence chain

1. Define the analyte, specimen, population, clinical purpose, user and setting precisely.
2. Convert performance claims into traceable metrics and acceptance criteria.
3. Link analytical and clinical evidence to each claim according to the assay and intended use.
4. Reflect limitations, interferences and warnings consistently in risk management and labelling.
5. Distinguish a missing report from an inadequate sample or evidence that does not apply to the submitted device.

Run the method on a live case before treating it as established. A procedure or certificate does not prove that records align, responsibilities are understood or the decision was executed. A real sample exposes handoff and version failures that a generic checklist often misses.

Three reviews before approval

First confirm the facts: current source, version, device or establishment scope, and the data behind the decision. Time-bound information or opportunity-specific assumptions should carry a date and should not become a permanent rule by accident.

Then run a cross-functional review. Regulatory, quality, product, operations or channel owners should participate according to the subject. The purpose is to expose any gap between the controlled record and what the organisation can actually execute while keeping one accountable decision owner.

Finally assess downstream impact. Identify the documents, records, versions and systems that must change, together with the evidence that will demonstrate implementation and outcome. A decision without follow-through usually reappears as the next change, audit or tender gap.

Questions that slow down a weak decision

• Is the scope tied to a known product, establishment or opportunity?
• Is one approved version used by every relevant owner?
• Does each gap have an owner, date and closure evidence?
• What new information would reopen the decision?

Where control is usually lost

Breakdowns tend to start with unverified inputs, different versions across functions or an exception with no owner and closure date. Records also lose value when they describe the event without showing who decided, why the decision was justified and what evidence would cause it to change.

The operating deliverable

An IVD claim-evidence register with applicability and consistency gaps.

The deliverable should state scope, assumptions, sources, versions, owners and closure criteria. That structure lets the team update a decision when new evidence appears without rebuilding the file from the beginning.

Basier scope and limits

Basier supports this work through Technical documentation and product compliance by reviewing evidence, structuring the operating record and testing gaps with the team. Basier does not issue authority decisions or guarantee acceptance, certification, qualification or award. Relevant service: Technical Documentation and Product Compliance

References: [1] [2]